Evidence Notes · No. 04
← All notesImplants that hold the prostate open rather than removing it. Improvement in days, usually no catheter, and the best-preserved sexual function of any BPH procedure — bought at a real cost in completeness.
UroLift, also called the prostatic urethral lift, treats an enlarged prostate without removing any tissue. Small permanent implants are placed through the urethra to hold the obstructing lobes of the prostate apart, opening the channel mechanically rather than cutting, heating or shrinking it.
Its distinctive claim is speed with preservation: improvement within days rather than months, no catheter for most men, a return to normal activity in about a week, and — uniquely consistently among BPH procedures — no new erectile or ejaculatory dysfunction in the pivotal randomised trial.
The trade-off is equally consistent. UroLift relieves obstruction less completely than an operation that removes tissue, and the evidence on how often men need something further is genuinely conflicting: the same procedure looks best-in-class in one analysis and worst-in-class in another, depending on what is being counted and against whom.
So what does the research actually show?
| Outcome | What the evidence suggests |
|---|---|
| Urinary symptoms | IPSS improvement was 88% greater than sham at three months in the pivotal randomised trial, and remained 36% better than baseline at five years.1, 2 |
| Urinary flow | Maximum flow was 44% above baseline at five years — a real improvement, and smaller than TURP achieves.2 |
| Speed | Symptoms and quality of life improved by two weeks, with return to normal physical activity in an average of 8.6 days.2 |
| Catheter | Usually avoided. Most men go home without one. |
| Surgical retreatment | 13.6% over five years in the pivotal trial — higher than TURP in one large database analysis, and the lowest among minimally invasive options in another.2, 9, 10 |
| Erections and ejaculation | No new sustained erectile or ejaculatory dysfunction over five years of the pivotal trial.2 |
| Best-established anatomy | Prostates of 30–80 mL with lateral-lobe obstruction; separate approved evidence covers an obstructing median lobe.1, 8 |
These are study averages, not guarantees for an individual patient.
UroLift treats lower urinary tract symptoms caused by benign prostatic hyperplasia — non-cancerous enlargement of the prostate.
The prostate sits below the bladder and surrounds the urethra, the tube urine passes through. As the two side lobes enlarge, they press inwards and narrow that channel, producing a weak stream, hesitancy, stopping and starting, incomplete emptying, urgency, frequency and repeated waking at night.
The procedure is performed through the urethra using a telescope. There is no external incision. Small implants, each consisting of a nitinol tab, a monofilament suture and a stainless steel tab, are deployed through the prostate to pull each lobe outwards and hold it there. The number used depends on the size and shape of the gland; a small series of younger men averaged two and a half.
The implants are permanent. Nothing is cut away, vaporised or shrunk, and no tissue is sent for laboratory analysis.
The mechanism is purely mechanical, and that explains most of the treatment's profile.
Because the obstruction is relieved by physically retracting tissue rather than destroying it, there is no dead tissue to be reabsorbed, no swelling phase and no thermal injury. Laboratory and clinical work on the implant describes exactly this: the prostatic urethra is widened immediately, without a systemic tissue effect.7
Three practical consequences follow:
The same mechanism sets the ceiling on what UroLift can achieve. Tissue that has been held aside is still there. If the gland is very large, if the obstruction comes from a median lobe protruding into the bladder, or if the prostate later continues to grow, retraction may not be enough.
Yes, in appropriately selected men — and the trial design behind that answer is unusually good.
The pivotal L.I.F.T. study randomised 206 men aged 50 or over at 19 centres in North America and Australia, in a 2:1 ratio, to UroLift or a blinded sham procedure. Entry required an IPSS above 12, a maximum flow of 12 mL/second or less, and a prostate of 30–80 cc.1
At three months — the blinded comparison — symptom improvement after UroLift was 88% greater than after the sham procedure.2
That sham control matters more than any other single feature of the evidence in these notes. Undergoing a procedure improves symptom scores by itself; without a sham arm there is no way to separate the device from the experience of being treated.
Men treated with UroLift were then followed for five years. At that point, compared with baseline:
A meta-analysis of five studies with at least 24 months of follow-up — 386 patients, of whom 322 were still available at two years — found mean IPSS reductions of 9.1 points in the randomised studies and 10.4 points in the non-randomised ones, with maximum flow improving by 3.7 and 3.0 mL/second respectively.4
The closeness of those randomised and non-randomised figures is itself reassuring. In several other minimally invasive treatments the uncontrolled studies report roughly twice the benefit of the controlled ones.
Against a sham procedure
88%greater IPSS gain, 3 months
206 men, blinded, 2:1. The sham arm is what separates the device from the effect of having had something done to you.
Symptom score at five years
36%better than baseline
Same men, followed to five years. Real, and smaller than an operation that removes tissue achieves.
Back to normal activity
8.6days, average
Most men avoid a catheter entirely. This is the number that makes UroLift different.
The International Prostate Symptom Score is a seven-question questionnaire covering incomplete emptying, frequency, intermittency, urgency, weak stream, straining and waking at night. It runs from 0 to 35:
A change of about three points is noticeable to the person experiencing it. When NICE assessed UroLift it noted a weighted mean improvement of between 9.22 and 11.82 points, against a published threshold for "marked improvement" of 8.80 — so the average result clears that bar.6
It is worth holding two things together here. The improvement is real and worthwhile. It is also, on average, smaller than TURP or HoLEP produce, and NICE said so explicitly in both its 2016 and 2021 assessments.5, 6
Maximum urinary flow, or Qmax, improved by 44% from baseline at five years in the pivotal trial, and by around 3.0 to 3.7 mL/second at two years in the pooled analysis.2, 4
That is a genuine change, and it is modest next to the doubling commonly seen after enucleation. Network meta-analyses of randomised evidence consistently place the tissue-removing procedures ahead of the mechanical and ablative ones on objective flow measures.11
Flow also depends on the bladder, not only the outlet. A bladder muscle weakened by years of pushing against an obstruction may not produce a strong stream even when the obstruction has been dealt with properly.
This is where UroLift is genuinely distinctive.
Symptoms and quality of life were significantly improved by two weeks in the pivotal trial, and men returned to their preoperative level of physical activity in an average of 8.6 days.2
Most men avoid a postoperative catheter altogether. There is no phase of tissue sloughing, no weeks of fluctuating symptoms, and no period during which things get worse before they get better — all of which are ordinary parts of recovery after steam ablation or enucleation.
For a man who cannot easily take weeks away from work, or who finds the prospect of a catheter genuinely unacceptable, this is not a minor advantage.
Temporary problems still occur: burning, urgency, blood in the urine, pelvic discomfort and occasionally difficulty passing urine. They are usually mild and usually settle within two to four weeks.
Improvement was maintained through five years in the pivotal randomised trial, with no late device failures reported.2
A French single-centre series covering seven years of practice reported that over 60% of men had needed no additional treatment at five years.19
Two qualifications belong alongside those figures.
First, the blinded comparison ended at three months; everything after that is follow-up of treated men, not continued randomised comparison against anything.
Second, five-year durability is not lifetime durability, and the prostate continues to grow. TURP and HoLEP have follow-up extending well beyond ten years. UroLift does not.
This is the least settled question about UroLift, and the published answers genuinely disagree.
The pivotal trial reported 13.6% surgical retreatment over five years.2
A large database analysis using TriNetX compared reintervention after UroLift, TURP and photoselective vaporisation, and found UroLift had the higher reintervention rate at four years.9
The Cochrane network meta-analysis of 27 randomised trials and 3,017 men reached what looks like the opposite conclusion: among the minimally invasive treatments assessed — once water-vapour therapy and iTind were set aside, both having only three-month data — UroLift had the highest likelihood of being the most effective for avoiding retreatment.10
Both can be true, because they are answering different questions. Compared with an operation that removes the obstructing tissue, UroLift is more likely to need repeating. Compared with the other treatments that leave tissue in place, it performs well. The comparator, not the procedure, drives the headline.
A head-to-head real-world comparison against Rezūm found a 25% retreatment rate after UroLift against 8.3% after Rezūm in the matched groups — but with only 24 patients in each arm after matching, and the difference did not reach statistical significance.12
The fair summary is that retreatment after UroLift is more likely than after TURP or HoLEP, is probably comparable to or better than most other tissue-sparing options, and cannot be quoted to you as a single reliable percentage.
Why you will see three different answers 13.6% at five years in the trial. The highest rate of the three when set against TURP and vaporisation in a database study. The best of the minimally invasive options in a Cochrane ranking. Nobody is being dishonest — the comparator decides the answer, so ask what any quoted figure was compared against.
Most reported problems are mild, temporary and confined to the first few weeks: burning or pain on passing urine, blood in the urine, urgency and frequency, pelvic discomfort, and occasionally temporary difficulty passing urine requiring a catheter.
Both NICE assessments concluded that UroLift's clearest advantage over TURP and HoLEP lies in this domain — comparable or slightly inferior symptom outcomes, but a distinctly better profile of minimal and mild complications.5, 6
The Cochrane network meta-analysis similarly found that minimally invasive treatments as a group produce a large reduction in major adverse events compared with TURP, though it rated the overall certainty of that body of evidence as low to very low.10
One counterweight deserves stating. An analysis grading complications by severity using the Accordion system, applied to the pivotal trials of both devices, found cumulative five-year complication rates of 33.6% for UroLift against 15.4% for Rezūm, driven largely by retreatment and implant removal rather than by anything happening in the first weeks.13
Longer-term possibilities include implant encrustation or stone formation on an implant, implant migration or extrusion, persistent symptoms, and the need for a further procedure — which, if it becomes a TURP or an enucleation, means operating around implants that are already in place.
The evidence is consistently reassuring, and better than for most alternatives.
The pivotal randomised trial reported no new sustained erectile dysfunction across five years.2
A 2026 systematic review and meta-analysis of minimally invasive treatments — 77 studies and 11,477 patients — found that erectile function scores improved significantly after UroLift.17
An improvement in average scores should be read carefully. Relieving severe urinary symptoms improves sleep, mood and confidence, all of which affect erections. It is more accurate to say that UroLift does not damage erectile function, and that men often feel better generally, than to say the device improves erections.
This is UroLift's strongest single claim, and the evidence behind it is unusually consistent.
The pivotal trial reported no de novo, sustained ejaculatory dysfunction over five years.2 The BPH6 randomised comparison against TURP found ejaculatory function preservation significantly favouring UroLift.3 The Cochrane network meta-analysis ranked UroLift the most likely of the minimally invasive treatments to be best for ejaculatory function.10 The 2026 meta-analysis found UroLift improved both the function and the bother components of the ejaculatory questionnaire, where Rezūm improved only bother.17
Set against conventional TURP, where a quarter to two-thirds of men lose forward ejaculation depending on how it is measured, and conventional HoLEP, where most men do, this is a substantial difference and it is not seriously contested.
No new sustained ejaculatory dysfunction across five years of the pivotal trial — and the top ranking for ejaculatory function in a Cochrane network meta-analysis. On this one question, UroLift wins.
For a small number of men this is the whole question, and there is direct evidence.
Twenty men with a mean age of 44.5 years, all wanting to preserve ejaculation for future fatherhood, underwent UroLift and had formal semen analysis before and six months after treatment. No retrograde ejaculation occurred, and there was no significant change in sperm count, volume, pH, motility, vitality or morphology. Over a mean follow-up of three years, maximum flow rose by 64%, residual urine fell by 67% and IPSS fell by 60%.14
Twenty men is a very small study. But it is a study that measured the actual thing, in the men who actually care about it, rather than inferring fertility from a questionnaire — and no other BPH procedure has an equivalent.
The pivotal evidence covers prostates of 30 to 80 cc with lateral-lobe obstruction.1 That is where effectiveness, five-year durability and retreatment rates are best established.
Beyond that range the picture thins out. UroLift has been used outside that range, and a Japanese series has reported useful early improvement, but the evidence does not support treating a very large prostate as equivalent to a trial-sized one.
Anatomy matters more here than volume alone. Retraction works when there is tissue that can be pulled aside. It works less well when the obstruction is a fixed bladder neck, a urethral stricture, or a gland whose shape leaves nowhere for the lobes to go.
Yes, with its own evidence — which is worth knowing, because a median lobe rules out several other minimally invasive options.
The MedLift study was a regulator-approved extension of the pivotal trial specifically in men with an obstructive median lobe. Symptom improvement was 170% greater than sham at three months, with better quality of life, flow and BPH Impact Index. Compared with TURP, symptom and quality-of-life scores were significantly better at one and three months, and ejaculatory function scores were superior at every time point. Outcomes in 187 real-world median-lobe patients matched the trial results at 3, 6 and 12 months.8
A median lobe is therefore not a reason to exclude UroLift — provided it is properly identified beforehand by cystoscopy or imaging, and provided the person treating it has experience with that configuration.
Often, yes, and this widens who can be offered treatment.
A systematic review of ten studies of UroLift under local anaesthesia — topical lidocaine, prostatic nerve blocks, transurethral intraprostatic anaesthesia, with or without light sedation — found satisfactory pain control and high tolerability, with visual analogue pain scores between 0.75 and 5.0 out of 10. The authors noted the absence of a standardised protocol, which makes comparison between studies difficult.15
For a man in his eighties with cardiac or respiratory disease, avoiding a general anaesthetic can be the deciding factor in whether any treatment is possible at all. Systematic review evidence supports minimally invasive options including UroLift in men over 75.16
There is direct randomised evidence, and it is admirably clear about the trade.
The BPH6 trial randomised 80 men across ten European centres and followed them for two years. TURP produced greater improvement in both IPSS and maximum flow. Quality of life and BPH Impact Index were not statistically different between the arms. UroLift was superior on quality of recovery, on preservation of ejaculatory function, and on the composite BPH6 endpoint. TURP significantly compromised continence at two weeks and three months. Only UroLift produced a statistically significant improvement in sleep.3
A more recent randomised comparison against monopolar TURP reported the same pattern: shorter hospital stay and better erectile and ejaculatory function after UroLift, no stress incontinence after UroLift against 6.7% after TURP, and less satisfactory IPSS improvement than TURP. The published report does not give the symptom figures themselves, which limits how much weight it can carry.18
The trade is therefore not in dispute. TURP relieves the obstruction more completely. UroLift leaves sexual function, continence and your calendar alone.
Choose UroLift for
The cost: a smaller improvement in symptoms and flow, and roughly one man in seven needing further surgery within five years.
Choose TURP for
The cost: ejaculation in most men, a catheter, an inpatient stay, and continence disturbed for the first three months.
There is no adequately powered randomised comparison, and the two are not really competing for the same patient.
HoLEP removes most of the obstructing adenoma, works at any prostate size, and has durability evidence beyond ten years — at the cost of forward ejaculation in the large majority of men. UroLift removes nothing, works within a defined size range, has five-year evidence, and preserves ejaculation.
NICE's economic modelling found UroLift performed as a day case saved £1,230 per person compared with HoLEP, alongside its finding that HoLEP produced better symptom and flow outcomes.5 Both statements are true simultaneously, which is roughly the shape of the whole decision.
This comparison is contested, and it is worth seeing why.
NICE's 2021 assessment concluded that UroLift appears superior to Rezūm for symptom severity and for measures of erectile and ejaculatory dysfunction.5
Two later analyses point the other way. A propensity-matched real-world comparison found greater symptom improvement and a lower reintervention rate after Rezūm.12 A severity-weighted complication analysis found a three-fold higher long-term complication burden after UroLift, driven by retreatment and implant removal.13
The studies pointing towards Rezūm are observational and small; the assessment pointing towards UroLift drew on the pivotal trials, which enrolled different populations under different protocols. Neither is decisive, and there is no randomised head-to-head trial.
What can be said with confidence is the shape of the difference: UroLift works immediately and usually without a catheter; Rezūm works gradually and usually with one. Both preserve sexual function far better than tissue-removing surgery.
Direct comparisons are scarce and most evidence is indirect.
Network meta-analyses find that the tissue-removing procedures — Aquablation and TURP — improve the urinary measures more, while UroLift improves sexual function relative to TURP, though not relative to Aquablation.11, 20 A network meta-analysis restricted to reintervention found broadly comparable short-term rates across the newer procedures, and emphasised the shortage of long-term direct comparisons.21 A comparison against prostatic artery embolisation found similar efficacy and safety.22
Against iTind, the practical distinction is that UroLift leaves a permanent implant and iTind does not, while UroLift has the larger evidence base and randomised five-year follow-up.
UroLift is worth discussing for a man who has:
Another approach is likely to suit better when:
Depending on anatomy and priorities, that may point towards Rezūm, iTind, Aquablation, TURP, HoLEP or prostatic artery embolisation.
The answer depends on which claim is being made.
A sham-controlled multicentre randomised trial with five-year follow-up, supported by a 386-patient pooled analysis at two years.1, 2, 4
Consistently reported across randomised and observational studies, and confirmed in direct comparison with TURP.2, 3
Randomised trial evidence, a randomised comparison against TURP, a Cochrane network meta-analysis ranking and a large meta-analysis all agree.2, 3, 10, 17
No new sustained erectile dysfunction in the pivotal trial, and improved scores in meta-analysis — though erectile outcomes have been studied less rigorously than urinary ones.2, 17
Established by direct randomisation and confirmed by two NICE assessments and by network meta-analysis.3, 5, 11
A regulator-approved trial extension with real-world confirmation, but smaller and less mature than the lateral-lobe evidence.8
Maintained improvement to five years in the pivotal population, and over 60% treatment-free at five years in an independent series.2, 19
13.6% at five years in the trial; the highest rate against TURP and vaporisation in a database analysis; the best of the minimally invasive options in a Cochrane ranking. The comparator determines the answer.2, 9, 10
A national assessment favours UroLift; two observational analyses favour Rezūm. No randomised head-to-head trial exists.5, 12, 13
Outside the trial range, and not supported by randomised evidence.
A single-centre series reaching seven years of practice is not the same as a ten-year outcome dataset.19
NICE first recommended UroLift in 2015 (MTG26) and updated that guidance in 2021 (MTG58). The recommendation is for use as a day-case procedure in men with prostates of 30–80 mL. NICE's clinical conclusion has been consistent across both assessments: symptom improvement is smaller than TURP and HoLEP achieve, the complication profile is better, and delivered as a day case the procedure saves money — an estimated £981 against bipolar TURP, £1,242 against monopolar TURP and £1,230 against HoLEP.5, 6
The day-case condition is not incidental. Almost the entire economic case, and much of the clinical one, rests on UroLift being done without an inpatient stay and without a general anaesthetic.
The day-case condition is doing real work here NICE recommends UroLift specifically as a day-case procedure. Almost the whole economic case, and much of the clinical one, depends on avoiding an inpatient stay and a general anaesthetic. Delivered any other way, the argument for it weakens considerably.
UroLift buys speed and preservation, and pays for them in completeness.
What it delivers is well established: symptom improvement 88% greater than sham at three months, sustained at 36% better than baseline at five years, with flow 44% better, recovery in around nine days, usually no catheter, and no new sustained erectile or ejaculatory dysfunction across five years of follow-up.2 For men who want to preserve fertility, it is the only procedure in these notes with published semen-analysis data showing no change.14
What it does not deliver is the degree of de-obstruction that removing tissue achieves. TURP beats it on symptoms and flow in direct randomised comparison, and NICE has said the same in two separate assessments.3, 5
The retreatment question remains genuinely open. Roughly one man in seven needed further surgery within five years in the pivotal trial. Whether that is a good or a poor figure depends entirely on what it is set against, and the published comparisons disagree.
UroLift suits a man with a moderately enlarged prostate, retractable lateral-lobe anatomy or a suitable median lobe, a strong wish to keep ejaculation and fertility, and a reason to avoid a catheter, a general anaesthetic or weeks away from work — who accepts a more modest improvement and the possibility of needing something further later.
It suits less well when the gland is large, when the obstruction will not respond to retraction, or when the priority is dealing with the problem once and definitively.
Every figure on this page is traceable to one of these. Where a study is small, unrandomised or industry-sponsored, that is stated in the text rather than left in the footnote.
Where this leaves you
UroLift is an excellent answer for a moderately enlarged, retractable prostate in a man who cannot afford weeks of recovery or the loss of ejaculation. It is the wrong answer for a large gland or a bladder in trouble, and I will say so.